Mylan Archives -

Generic drugmaker Viatris has become the first company to secure FDA approval for a biosimilar product that is

FDA okays Viatris’ insulin drug as first ‘interchangeable’ biosimilar

https://pharmaphorum.com/news/fda-okays-mylan-insulin-drug-as-first-interchangeable-biosimilar/

Close-up image of a firm handshake between two colleagues

News/ News/ Sales and Marketing

FTC clears Mylan merger with Pfizer’s Upjohn – with conditions

Phil Taylor competition, generic, M&A, Mylan, Pfizer, regulatory, Viatris 0 Comment

Mylan’s $12 billion takeover of Pfizer’s Upjohn unit has been cleared by the US authorities, but on the

FTC clears Mylan merger with Pfizer’s Upjohn – with conditions

https://pharmaphorum.com/news/ftc-clears-mylan-merger-with-pfizers-upjohn-with-conditions/

News

Coronavirus pandemic delay Mylan and Pfizer’s generics merger

Richard Staines coronavirus, COVID-19, generics, M&A, Mylan, Pfizer 0 Comment

Mylan’s merger with Pfizer’s off-patent drug business has been delayed until later this year because of the coronavirus

Coronavirus pandemic delay Mylan and Pfizer’s generics merger

https://pharmaphorum.com/news/coronavirus-pandemic-delay-mylan-and-pfizers-generics-merger/

Chinese people wearing surgical mask sitting in subway

News

COVID-19 could disrupt supplies of cheap generics, analysts warn

Richard Staines antivirals, coronavirus, COVID-19, generics, infectious diseases, manufacturing, Mylan, Teva, vaccine 0 Comment

An extended COVID-19 coronavirus outbreak could impact on supplies of generic drugs that many health systems rely on

COVID-19 could disrupt supplies of cheap generics, analysts warn

https://pharmaphorum.com/news/covid-19-could-disrupt-supplies-of-cheap-generics-moodys/

News/ News/ Sales and Marketing

Biogen claims victory in patent dispute with Mylan over MS drug Tecfidera

Phil Taylor Biogen, generic, Mylan, patent, Tecfidera 0 Comment

Shares in Biogen are on the rise after the company successfully defended its blockbuster multiple sclerosis drug Tecfidera

Biogen claims victory in patent dispute with Mylan over MS drug Tecfidera

https://pharmaphorum.com/news/biogen-claims-victory-in-patent-dispute-with-mylan-over-ms-drug-tecfidera/

Market Access/ News/ News

Chasing Mylan, Hikma tries again with rejected generic Advair in US

Phil Taylor Advair, asthma, Chronic Obstructive Pulmonary Disease, generic, GlaxoSmithKline, Hikma, Mylan, respiratory, Sandoz 0 Comment

UK-listed Hikma Pharma has filed a response to the FDA that it hopes will clear the way for

Chasing Mylan, Hikma tries again with rejected generic Advair in US

https://pharmaphorum.com/news/chasing-mylan-hikma-tries-again-with-rejected-generic-advair-in-us/

Market Access/ News/ News

Mylan’s Lantus biosimilar held up by manufacturing issue

Phil Taylor Biocon, biosimilar, Diabetes, insulin, Lantus, Mylan, Sanofi 0 Comment

Mylan’s hopes of grabbing a slice of the big US market for insulin glargine – the active ingredient

Mylan’s Lantus biosimilar held up by manufacturing issue

https://pharmaphorum.com/news/mylans-lantus-biosimilar-held-up-by-manufacturing-issue/

Market Access/ News/ News

Mylan up on OK for generic of Lilly’s $2bn cancer drug Alimta

Phil Taylor Alimta, Eli Lilly, generic, lung cancer, Mylan 0 Comment

Shares in Mylan have risen after the FDA gave a tentative approval to its generic version of Eli

Mylan up on OK for generic of Lilly’s $2bn cancer drug Alimta

https://pharmaphorum.com/news/mylan-up-on-ok-for-generic-of-lillys-2bn-cancer-drug-alimta/

News

Hikma buys potential Epipen rival from troubled Insys

Richard Staines generic, Hikma, Mylan 0 Comment

UK-based pharma Hikma has snapped up assets from embattled Insys Therapeutics, including potential generics of Mylan’s Epipen allergic

Hikma buys potential Epipen rival from troubled Insys

https://pharmaphorum.com/news/hikma-buys-potential-epipen-generic-from-insys/

Trending

Mylan

Login